It is clear that staging of prostate cancer is undergoing significant changes. Several new tests, markers, and imaging modalities are now available that can improve staging accuracy. Furthermore, there are many newer models available now that incorporate information from demographic, clinical, biochemical, imaging, systematic biopsy, and novel molecular markers into one unified predictive model. Neural network technology is also now available and seems very promising in predicting pathological stage using the abovementioned information. The exact role of these newer developments will be established by large, multicentric randomized trials comparing performance of these models. Once validated, these models will immensely help in patient management and in minimizing staging inaccuracy.
© 2000 Medscape
Cite this: Evaluation of the Patient With Prostate Cancer - Medscape - Sep 14, 2000.